Martin Shkreli’s December 3, 2025: Short Call — REKT. Co's Duchenne Muscular Dystrophy Candidate Looks Promising...

For a change, I now think / suspect he actually had a cash position on -- betting on a decline in CAPR stock.

He guessed wrong, on the clinical trial that the company was/is running -- preposterously thinking that he understood more organic chemistry -- in the form of cardiosphere-derived cells, or CDCs, which is an endogenous population of stromal cells derived from cells of healthy human hearts -- than the company's Johns Hopkins credentialed / Ph.D. leadership. Yep, he was wiped out -- as the the stock leapt over 370 percent today (see at right) -- on excellent interim trial results.

In a word, he looked. . . positively rekt.

And if you want to see him burping, incessantly -- in a bout of panicked indigestion, this morning -- here's that live stream, from his YouTube channel.

He still has a baby to feed -- and Christmas is almost here.

My best bet is that he is penniless -- again.

We shall see.

But people who follow him, based on his supposed bio-science / pharma-science chops. . . are uniformly. . . idiots.

Onward, and out [yep, this is power-alley stuff].

नमस्ते